Correspondence 0001654954-23-002716 from Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics, Inc.
Date: March 13, 2023 · CIK: 0001853816 · Accession: 0001654954-23-002716

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-270195

Date

March 14, 2023

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

Dermata Therapeutics, Inc.

Letter

Re:

drma_corresp.htmMarch 13, 2023

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Dermata Therapeutics, Inc.

Registration Statement on Form S-1 (Registration No. 333-270195), as amended - Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration statement on Form S-1 (333-270195) (the “Registration Statement”), hereby concurs in the request by Dermata Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 1:00 P.M. (Eastern Time), or as soon as practicable thereafter, on March 14, 2023, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

drma_corresp.htmMarch 13, 2023

 VIA FACSIMILE AND EDGAR

 U.S. Securities and Exchange Commission

 Division of Corporate Finance

 Washington, DC 20549

    Re:

   Dermata Therapeutics, Inc.

     Registration Statement on Form S-1 (Registration No. 333-270195), as amended - Concurrence in Acceleration Request

 Ladies and Gentlemen:

 H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration statement on Form S-1 (333-270195) (the “Registration Statement”), hereby concurs in the request by Dermata Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 1:00 P.M. (Eastern Time), or as soon as practicable thereafter, on March 14, 2023, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

      Very truly yours,

   H.C. WAINWRIGHT & CO., LLC

    By:  /s/ Edward D. Silvera

  Name: Edward D. Silvera

        Title: Chief Operating Officer

SecProbe.io